As combination therapy and prior treatment can complicate interpretations, we investigated the relationship between baseline levels of sEV-VEGF and outcomes in a cohort of newly diagnosed cancer patients who received bevacizumab monotherapy. The gene discussed is VEGFA; the disease is cancer.